UBS Group
SNDX icon

UBS Group’s Syndax Pharmaceuticals SNDX Stock Holding History

UBS Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,800
Closed -$287K – 9839
2023
Q3 		$287K Buy
+19,800
New +$375K ﹤0.01% 5088

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

UBS Group's SNDX Position: Q2 2026 in Review

UBS Group increased its Syndax Pharmaceuticals (SNDX) stake by 64% in Q2 2026, buying an estimated $15.4M and bringing the position to 1,893,750 shares worth $41.4M. The position accounts for 0.01% of the portfolio, ranked #1939.

UBS Group first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • UBS Group held 1,893,750 shares of Syndax Pharmaceuticals worth $41.4M as of Q2 2026.
  • UBS Group bought 740,088 Syndax Pharmaceuticals shares in Q2 2026, an estimated $15.4M.
  • Syndax Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1939 holding.
  • UBS Group first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.